CTSO Cytosorbents Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTSO

Price (delayed)

$4.91

Market cap

$15.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.8

Enterprise value

$38.33M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 35
Relative Profitability: Rel. Profitability: 19

CytoSorbents Corporation, formerly MedaSorb Technologies Corporation is a development-stage therapeutic medical device company. As of December 31, 2011, the Company had developed and focuses on commercializing a blood purification technology ...

Highlights
The gross profit rose by 9% year-on-year
The gross margin is up by 5% YoY
The equity has dropped by 134% since the previous quarter and by 106% year-on-year
CTSO's net income has dropped by 85% year-on-year and by 54% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.cytosorbents.com
Peers: BSX NEPH

Key stats

What are the main financial stats of CTSO

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
-7.71%
1 week
-14.31%
1 month
-33.65%
1 year
-74.45%
YTD
-61.58%
QTD
-34.36%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$37.22M
Gross profit
$26.65M
Operating income
-$12.93M
Net income
-$18.21M
Gross margin
71.6%
Net margin
-48.9%
CTSO's net income has dropped by 85% year-on-year and by 54% since the previous quarter
The net margin has dropped by 79% year-on-year and by 53% since the previous quarter
Cytosorbents's operating margin has increased by 20% YoY and by 7% QoQ
CTSO's operating income is up by 18% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does CTSO's price correlate with its fundamentals

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
N/A
P/S
0.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.03
CTSO's EPS has plunged by 61% YoY and by 53% from the previous quarter
The equity has dropped by 134% since the previous quarter and by 106% year-on-year
The stock's price to sales (P/S) is 82% less than its 5-year quarterly average of 2.5 and 59% less than its last 4 quarters average of 1.1
Cytosorbents's revenue has increased by 3.1% YoY

Efficiency

How efficient is Cytosorbents business performance
The ROE has plunged by 170% from the previous quarter
The ROA has shrunk by 113% YoY and by 62% QoQ
The ROIC has plunged by 96% YoY and by 82% from the previous quarter
CTSO's ROS has plunged by 65% from the previous quarter and by 64% YoY

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The quick ratio has shrunk by 73% YoY and by 36% QoQ
CTSO's current ratio has dropped by 72% year-on-year and by 39% since the previous quarter
The equity has dropped by 134% since the previous quarter and by 106% year-on-year
The debt has increased by 9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.